All In Biotech

Drug Trial Radar · NCT00631566

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons

Last checked: Nov 20, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

May 2007

Primary completion

May 2017

Study completion Oct 2017

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Infectious Diseases Clinical Research Program; National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research Program
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA colonization and infection. This study will also investigate the utility of decolonization procedures for clearance of MRSA carriage and prevention of MRSA infections. Finally, the molecular characteristics and the antimicrobial sensitivities of isolates in this population will be determined.

Conditions

  • HIV Infections
  • Staphylococcal Infections

Interventions

  • Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%Drug

    BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649). pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration. Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.

  • PlaceboDrug

    Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA ColonizationTime frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Naval Medical Center San Diego/Infectious Disease Division

    San Diego, California

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • San Antonio Military Medical Center (BAMC/WHMC)

    San Antonio, Texas

  • Naval Medical Center Portsmouth

    Portsmouth, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.